The Next Science Ltd (ASX: NXS) share price has more than tripled to $3.09 since its April 2019 initial public offering at $1 per share.
Today the group reported an operating cash loss of US$3.43 million on revenue of US$1.2 million for the quarter ending June 30, 2019.
Next Science already has four anti-bacterial FDA-approved products (used to treat common wounds or lacerations) in the U.S. market under its ‘Xbio Family’ generic label.
Like any good ASX biotech, it also has multiple new products in the pipeline for potential FDA approval and commercialisation.
It also has an acne treatment product it expects to launch in Australia in the second half of 2019 and reported today that it has made significant progress over the first half of 2019 in getting more products approved.
It has US$23.9 million cash on hand as at June 30 2019 to meet its cash outflows and fund its upcoming and ongoing clinical trials. Notably these can be expensive.
Next Science currently has a market cap around $550 million, which looks very high to me relative to its cash flows.
Another speccy biotech widely fancied by punters to hit the big time is Paradigm Group Ltd (ASX: PAR). It could be worth more research for anyone with a high risk tolerance.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.